Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 16/20 | 0.81 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16117862 | 1.00 | KRAS (0.81) | KRASEGLN1EGFRSCD | |
| SCHEMBL31672374 | 0.96 | KRAS (0.79) | KRASEGLN1SCD | |
| SCHEMBL16101851 | 0.96 | KRAS (0.79) | KRASEGLN1SCD | |
| SCHEMBL16103039 | 0.90 | KRAS (1.00) | KRASEGLN1 | |
| SCHEMBL31672334 | 0.90 | KRAS (1.00) | KRASEGLN1 | |
| SCHEMBL16094086 | 0.88 | KRAS (0.63) | KRASEGFR | |
| SCHEMBL16121832 | 0.88 | KRAS (0.63) | KRAS | |
| SCHEMBL20515199 | 0.88 | KRAS (0.66) | KRASEGFR | |
| SCHEMBL31672354 | 0.88 | KRAS (0.77) | KRASEGLN1 | |
| SCHEMBL16099895 | 0.88 | KRAS (0.77) | KRASEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | claimed |
| US-20240342285-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-10-17 | — | — | US | claimed |
| CN-118767140-A | Combined medicine for preventing and/or treating solid tumors | 海创药业股份有限公司 | 2024-10-15 | — | — | CN | claimed |
| EP-4377446-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | Iovance Biotherapeutics, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2023009716-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20250281607-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| US-RE50527-E1 | Covalent inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025051110-A1 | COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES | INSILICO MEDICINE IP LIMITED (CN) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | disclosed |
| US-20240343813-A1 | COMBINATION THERAPY AND RELATED METHODS | BICARA THERAPEUTICS INC. | 2024-10-17 | — | — | US | disclosed |
| US-20240342285-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-10-17 | — | — | US | disclosed |
| CN-118767140-A | Combined medicine for preventing and/or treating solid tumors | 海创药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4378478-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2024-06-05 | — | — | EP | disclosed |
| EP-4377446-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | Iovance Biotherapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117677398-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023009716-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023008462-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343813-A1 | COMBINATION THERAPY AND RELATED METHODS | EGFR, HRAS, KRAS | KRAS 3/4885EGLN1 1206/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.